This is the text extract for 2010-12 Schedule Dispatch, browse documents here.

---

18 November 2010 December 2010 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the December 2010 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings  Rivaroxaban (Xerelto) tab 10 mg, 15 tab pack (p’code 2336324) and 30 tab pack (p’code 2336316) – Special Authority – Retail pharmacy  Gemfibrozil (Lipazil) tab 600 mg (p’code 472875)  Menthol (Midwest) crystals, 25 g – Only in combination (p’code 2377209)  Sulphur (Midwest) precipitated 100 g – Only in combination (p’code 2121158)  Moxifloxacin (Avelox) tab 400 mg – Special Authority – Retail pharmacy (p’code 2022362)  Itraconazole (Itrazole) cap 100 mg – Retail pharmacy-Specialist (p’code 2354322)  Escitalopram (Loxalate) tab 10 mg (p’code 2347792) and 20 mg (p’code 2347806)  Sertraline (Arrow-Sertraline) tab 50 mg (p’code 2376520) and 100 mg (p’code 2376539)  Glycerin with sucrose (Ora-Sweet) suspension – Only in combination with Ora-Plus (p’code 2377241)  Glycerin with sodium saccharin (Ora-Sweet SF) – Only in combination with Ora-Plus (p’code 2377268)  Methyl hydroxybenzoate (Midwest) powder, 25 g (p’code 2018853)  Methylcellulose with glycerin and sucrose (Ora-Blend) suspension – Only in combination (p’code 2377217)  Methylcellulose with glycerin and sodium saccharin (Ora-Blend SF) suspension – Only in combination (p’code 2377225)  Methylcellulose (Ora-Plus) suspension – Only in combination (p’code 2377233)  Propylene glycol (Midwest) liq, 500 ml – Only in extemporaneously compounded methyl hydroxybenzoate 10% solution. (p’code 2177447)  Sodium bicarbonate (Midwest) powder BP, 500 g – Only in extemporaneously compounded omeprazole suspension (p’code 2032880) Changes to restrictions  Levomepromazine – chemical name change from methotrimeprazine  Multiple Sclerosis Treatments – amended stopping criteria  Temozolomide (Temodal) cap 5 mg, 20 mg, 100 mg and 250 mg – amended Special Authority criteria Decreased subsidy

Chemical Presentation Fully brands subsidised Partially subsidised brands

Loperamide hydrochloride Cilazapril Labetalol Propranolol Nifedipine Isosorbide mononitrate Menthol Amoxycillin A392515 - qA17803

Tab 2 mg Tab 0.5 mg, 2.5 mg and 5 mg Tab 50 mg, 100 mg and 200 mg Cap long-acting 160 mg Tab long-acting 30 mg and 60 mg Tab long-acting 60 mg Crystals, 25 g Cap 250 mg and 500 mg

Nodia

Zapril

Inhibace

Hybloc Cardinol LA Adefin XL Duride PSM Midwest

Alphamox

Apo-Amoxi Page 1 of 3

---

Naproxen sodium Interferon beta-1-beta Carboplatin Oxaliplatin Calcium folinate Methotrexate

Tab 275 mg Tab 550 mg Inj 8 million iu per 1 ml Inj 10 mg per ml, 45 ml and 100 ml Inj 50 mg and 100 mg Inj 1 mg for ECP Inj 1 g Inj 100 mg per ml, 10 ml and 50 ml Inj 1 mg for ECP Inj 100 mg and 200 mg Inj 2 mg per ml, 50 ml and 50 ml Inj 1 mg for ECP Inj 30 mg, 100 mg, 150 mg, 300 mg and 600 Inj 1 mg for ECP Eye drops 0.5% Powder, 25 g

Sonaflam Synflex Betaferon Carboplatin Ebewe Oxaliplatin Ebewe Baxter Calcium Folinate Ebewe Methotrexate Ebewe Baxter Doxorubicin Ebewe Epirubicin Ebewe Baxter Paclitaxel Ebewe Baxter Chlorafast ABM Midwest PSM ABM Midwest PSM

Doxorubicin Epirubicin Paclitaxel

Chloramphenicol Methyl hydroxybenzoate

Chlorsig

Propylene glycol

Liq, 500 ml

Increased Subsidy

Chemical Presentation Fully brands subsidised

Chlorhexidine gluconate Doxorubicin

Mouthwash 0.2%, 200 ml OP Inj 10 mg and 50 mg Inj 1 mg for ECP

Rivacol Doxorubicin Ebewe Baxter

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

Varenicline (Champix) Special Authority clarification Champix tablets were listed fully subsidised as a smoking cessation treatment, subject to Special Authority criteria, from 1 November 2010. One of the Special Authority criteria refers to patients not having used varenicline in the last 12 months (criterion 4). We would like to clarify that this means patients must not have used subsidised varenicline in the last 12 months. This criterion has already been amended on the Special Authority form.

A392515 - qA17803

Page 2 of 3

---

New CFC-free Salbutamol with Ipratropium Bromide Aerosol Inhaler A new CFC-free salbutamol with ipratropium bromide aerosol inhaler will be available early in 2011 as a replacement for Combivent. Duolin HFA from Rex Medical has gained registration by Medsafe. Duolin HFA stock will be available and fully subsidised in the market in February 2011 at the following price and subsidy:

Chemical and strength Salbutamol 100 µg with 20 µg ipratropium Presentation Aerosol inhaler, CFC-free Pack size 200 doses OP Proposed price and subsidy $12.19

Combivent will continue to be listed at the current price and subsidy until stock is depleted, which is expected to be early in the new year

A392515 - qA17803

Page 3 of 3